Higher Education Level, Greater Disability Linked With Treatment Timing In Parkinson's Disease
Posted on: Monday, 13 July 2009, 15:44 CDT
Individuals who have higher levels of education and who are more impaired by Parkinson's disease appear to require treatment for their symptoms earlier than do other patients, according to a report posted online today that will appear in the September print issue of Archives of Neurology, one of the JAMA/Archives journals."Parkinson's disease is a chronic progressive neurodegenerative disease that leads to significant morbidity, disability and increased likelihood of institutionalization," the authors write as background information in the article. "In view of the potential for short-term and long-term drug complications, symptomatic treatment is customarily delayed in Parkinson's disease until the severity of motor symptoms results in functional impairment. Therefore, the initiation of symptomatic treatment is considered an early indicator of disease progression in Parkinson's disease and is used as an important benchmark in clinical trials."
Sotirios A . Parashos, M.D., Ph.D., of the Struthers Parkinson's Center, Golden Valley, Minn., and colleagues in the NET-PD Investigators group analyzed data from 413 patients with early, untreated Parkinson's disease who participated in two double-blind trials of experimental drugs. "Site investigators used their clinical judgment to determine when participants had reached a level of dysfunction sufficient to require symptomatic therapy in any one of three areas: ambulation [walking], activities of daily living or occupational status," the authors write.
After 12 months, the researchers assessed all the treatment groups to identify which patients had started taking medication for their symptoms—including levodopa or dopamine agonists, treatments that regulate the amount of the neurotransmitter dopamine. At this time, 200 of the 413 participants (48.5 percent) had started symptomatic treatment. Those who had higher levels of impairment and disability at the beginning of the study, as measured by several Parkinson's disease scales, were more likely to progress quickly.
Higher education levels were also independently associated with an earlier need for symptomatic treatment. "A possible explanation is that higher education may be associated with greater occupational demands and an increased need for symptomatic control," the authors write. "However, one might expect that occupations placing higher demands on physical abilities (usually associated with lower education levels) would be associated with a more pressing need for symptomatic control. An alternate possibility is that patients with higher education are likely to be better advocates for their health care needs and play a more active role in medical decision-making."
"Emotional, psychiatric and quality of life factors at baseline played a smaller role in determining need for symptomatic treatment and did not enter the final model when baseline impairment, disability and education were taken into account," they conclude. "The impact of the patient's education level on clinical management is an unexpected finding and merits further investigation."
------------
On The Net:
JAMA
Related Articles
- Genetic Changes Shown To Be Important Indicators For Disease Progression In Cervical Cancer Patients
- Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients
- A Broad-Spectrum Antibiotic with Activity Against MRSA and Pseudomonas Aeruginosa Would Earn a Higher Patient Share in the U.S. than in Europe for the Treatment of Hospital-Acquired Pneumonia
- Beyond Disease Management: Strategies for Improving Patient Care and Cutting Costs
- Top Tech-Savvy School Boards Announced By the Center for Digital Education and National School Boards Association
- New Data Confirm Durable Response of TNX-355 Regimens Through 48 Weeks in Treatment-Experienced HIV Patients
- Vicriviroc Demonstrates Potent and Sustained Viral Suppression in ACTG Phase II Clinical Study in Treatment-Experienced HIV Patients
- Optimer's Lead Antibiotic Candidate Moves Into Phase 2B/3 Clinical Trials for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
- New Planning Tool Streamlines Brachytherapy Treatments and Improves Patient Comfort
- Response of Homocysteine, Cystathionine, and Methylmalonic Acid to Vitamin Treatment in Dialysis Patients
User Comments (0)

RSS Feeds